Abcellera Biologics Inc (ABCL NASDAQ) stock market data APIs
$4.4901
0.15(3.3%)
as of January 12, 2026
Try our APIs with
free plan!
Abcellera Biologics Inc Financial Data Overview
Price chart is built with
Anychart
AbCellera Biologics Inc. engages in discovering and developing antibody-based medicines for indications with unmet medical need in the United States. Its product pipeline includes ABCL635, an antibody-drug candidate, which is in preclinical trial to treat metabolic and endocrine conditions; and ABCL575, a fully human, half-life extended monoclonal antibody, which is in preclinical trial for treating T-cell-mediated autoimmune conditions, such as atopic dermatitis. The company has a research collaboration and license agreement with Eli Lilly and Company; and partnership agreement with Viking Global Investors & ArrowMark Partners and Biogen Inc. AbCellera Biologics Inc. was incorporated in 2012 and is headquartered in Vancouver, Canada.
Prev. Close
4.4901
Open
4.6418
High
4.6764
Low
4.3866
52 wk Range
1.8906-6.515
Market Cap
1 353 M
Shares Outstanding
299 M
Revenue
35 325 K
EPS
-0.19
Beta
0.734
* We provide hundreds of fields of fundamental data, including EBITDA, P/E ratio, PEG ratio, trailing P/E, shareholders, insider transactions, technical metrics, dividends, splits, earnings, and more. Check out our Fundamental Data API.
ETFs with Abcellera Biologics Inc (top by weight)
Ticker
100-day Price Change
Weight
* We provide detailed information about ETF constituents through our Fundamentals API for ETFs. Read the documentation to learn more.
Why to choose EODHD?
Prices start at $19.99
24/7 Live support
Robust, powerful and reliable data
API Simplicity of a few lines of code
Try our APIs
with free plan!
Or get access to advanced financial data starting only $19.99
TRY NOW
Get Abcellera Biologics Inc data using free add-ons & libraries
Get Abcellera Biologics Inc Fundamental Data
Abcellera Biologics Inc Fundamental data includes:
- Net Revenue: 35 325 K
- EBITDA: -232 664 000
- Earnings Per Share:
- Income Statements
- Balance Sheets
- Cash flows
Plans with Fundamental data
Starting from
$
59.99
/mo.
End-of-day & Earnings data
What’s included:
- Latest Release: 2025-11-06
- EPS/Forecast: -0.14
What’s included:
- End of Day, Intraday and Live APIs
- Splits
- Dividends
Abcellera Biologics Inc News
New
Peter Thiel’s Incredible Advice for Anyone Looking to Grow Their Retirement Portfolio
Stephanie Keith / Getty Images News via Getty Images Key Points Thiel built $1B in his Roth IRA largely through early PayPal shares and private equity investments in startups before they went public...
3 Promising Penny Stocks With Market Caps Under $2B
As the Dow Jones and S&P 500 reach new all-time highs, investors are increasingly on the lookout for opportunities that can offer both stability and potential growth. Though often seen as a throwback ...
Sector Update: Health Care Stocks Rise Late Afternoon
Health care stocks rose late Thursday afternoon, with the NYSE Health Care Index and the State Stree PREMIUM Upgrade to read this MT Newswires article and get so much more. A Silver or Gold subscri...
AbCellera settles patent litigation with Bruker over microfluidic device tech
[The Patent Application Process Important Paperwork and Necessary Tools for Success] * Bruker Corp. (BRKR [https://seekingalpha.com/symbol/BRKR]) will pay AbCellera Biologics (ABCL [https://seeking...
Try our APIs
with free plan!
Or get access to advanced financial data starting only $19.99
TRY NOW
- Flexibility: No long-term commitments, just a minimum of one month
- Instant access: Get your API key and instructions within seconds of subscribing
All-In-One
$99.99/mo.
What’s included:
- API Calls per Day: 100 000/day
- API Requests per Min.: 1000/minute
- Type of Usage: Personal use
Data access:
Historical EOD, Fundamental, Real-Time, Intraday, Live (Delayed), Technical & Screener APIs, News Feed, 40 000 Stock Logos and many more. See a full list.
